Celgene abandoned a key drug application last week, sending the stock and sector into a tailspin that could signal an intermediate correction. …read more
Read more here: Celgene Shocker Could End Biotech Rally
Category: CELG, IBB
What NOT to buy during Presidents’ Day weekend salesPro golfer Kuchar agrees to pay Mexican caddie $50,000 following criticismHere’s the worst mistake people make that compromises their online securityCanada’s Freeland pushes end of steel, aluminum tariffs in meeting with PelosiTop Healthcare Stocks for February 2019
